The proportion of patients meeting HbA1c treatment goal of <7.0% at week 24; the proportion of patients having HbA1c lowered by 0.5% at week 24; the change from baseline over time of fasting plasma glucose, 2 h postprandial plasma glucose, fasting plasma insulin, free fatty acids, homoeostasis model assessment for insulin resistance (HOMA‐IR) and beta‐cell function (HOMA‐B), triglycerides, total cholesterol, high‐density lipoprotein cholesterol, and low‐density lipoprotein cholesterol levels. Here, INS is linked to Insulin resistance.